Cryptobiosis and its control in North American fishes.
Cryptobiosis is caused by the haemoflagellates Cryptobia bullocki and Cryptobia salmositica. These parasites infect food fishes (e.g. flounders, salmon) on both the Atlantic and Pacific coasts of North America and clinical signs of the disease include anaemia, and abdominal distention with ascites. The virulent factor in salmonid cryptobiosis, caused by C. salmositica, is a secretory metalloprotease (200 kDa). Fish mortality may be up to 100% in the absence of treatment, consequently strategies have been developed to protect them from disease/mortality. A single dose of a live vaccine protects fish for at least 2 years, and it is via the production of complement-fixing antibodies, enhanced phagocytosis and cell-mediated cytotoxicity. Inhibition of the parasite's cysteine protease by a monoclonal antibody reduces multiplication, infectivity and survival of the parasite. Consequently, the recombinant cysteine protease (49 kDa) of the parasite will be tested as a potential vaccine. The trypanocidal drug, isometamidium chloride (1.0 mg/kg), is effective (therapeutic and prophylactic) against C. salmositica in chinook salmon. Its efficacy is significantly enhanced if it is conjugated either to a monoclonal antibody or to polyclonal antibodies from immune fish. Selective breeding of Cryptobia-resistant brook charr (innate resistance to infection) is possible, and the resistant factor(s) is controlled by a dominant Mendelian locus. In these resistant charr the parasite is lysed via the alternate pathway of complement activation (innate immunity to infection). There are also Cryptobia-tolerant charr, fish that are susceptible to infection but have no clinical disease (innate resistance to disease). In these fish, one of the natural anti-proteases, alpha2-macroglobulin, neutralises the metalloprotease secreted by C. salmositica. Production of transgenic Cryptobia-tolerant salmon is an option to vaccination and or chemotherapy. Also, transgenic pathogen-tolerant animals may be an alternate strategy against other pathogens where the disease mechanism is similar to cryptobiosis.
Woo
P T
PT
Department of Zoology and Axelrod Institute of Ichthyology, College of Biological Science, University of Guelph, Ontario N1G 2W1, Guelph, Canada. pwoo@uoguelph.ca
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D005260:Female; D005393:Fish Diseases / Q000276:immunology / Q000469:parasitology* / Q000517:prevention & control; D005399:Fishes / Q000469:parasitology*; D016830:Kinetoplastida / Q000276:immunology; D008297:Male; D008666:Metalloendopeptidases / Q000276:immunology; D009656:North America; D018512:Parasitemia / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary; D011528:Protozoan Infections / Q000276:immunology / Q000517:prevention & control; D011529:Protozoan Infections, Animal; D016052:Protozoan Vaccines / Q000276:immunology / Q000627:therapeutic use; D014611:Vaccination / Q000662:veterinary
D000981:Antiprotozoal Agents; D016052:Protozoan Vaccines; D008666:Metalloendopeptidases